Rare High-Grade Thyroid Cancer Grew Into a 13 cm Neck Mass and Spread to the Lungs

A 58-year-old woman lived for six years with a steadily enlarging lump in her neck before the mass grew large enough to interfere with breathing and swallowing, prompting her to seek urgent surgical care. When clinicians finally measured the clinical mass, it spanned an extraordinary 13 centimeters across her neck, and computed tomography revealed a thyroid lesion cross-section of 12.4 by 7.7 centimeters along with bilateral pulmonary nodules that had quietly taken root in both lungs. The case, reported in detail in the journal BMC Endocrine Disorders, documents one of the more dramatic presentations of an unusual and recently formalized category of thyroid malignancy known as differentiated high-grade thyroid carcinoma, a tumor type that continues to challenge pathologists, endocrinologists, and surgeons alike.

Differentiated high-grade thyroid carcinoma entered the official medical lexicon with the 2022 revision of the World Health Organization classification of thyroid tumors. The category was created to capture a troubling intermediate entity: tumors that retain the recognizable microscopic architecture of differentiated thyroid cancer, the well-behaved papillary and follicular patterns that typically respond well to surgery and radioactive iodine, yet display unmistakable signs of aggressive biological behavior. Under the WHO definition, a differentiated high-grade tumor must show tumor necrosis, meaning patches of dead malignant tissue where the cancer has outgrown its blood supply, or an elevated mitotic count of at least five mitoses per two square millimeters, indicating rapid cellular division. Either finding, layered on top of differentiated morphology, signals a tumor that may behave far worse than its appearance alone would suggest.

The patient in this report arrived with classic compressive symptoms. Dyspnea, or difficulty breathing, and dysphagia, difficulty swallowing, are alarming signs when a neck mass is the culprit, because the thyroid gland sits directly in front of the trachea and esophagus. A six-year history of slow enlargement raises difficult questions about why earlier intervention did not occur, and the case underscores a persistent global problem: slowly growing thyroid masses can be tolerated or overlooked for years until they become bulky, symptomatic, and significantly harder to remove. By the time this patient reached the operating theater, the mass qualified as a giant clinical neck mass, a descriptive term for tumors large enough to distort cervical anatomy and complicate standard surgical technique.

In July 2024, the surgical team performed a total thyroidectomy, the complete removal of the thyroid gland, together with a bilateral central lymph node dissection clearing the compartment behind and beside the thyroid, and a right lateral neck dissection covering lymph node levels II through V. The extent of the operation reflects how thoroughly the disease had spread through the neck’s drainage basins. Pathological examination of the removed tissue confirmed bilateral differentiated high-grade thyroid carcinoma involving both thyroid lobes, with visible tumor necrosis, more than five mitoses per two square millimeters, and multifocal vascular invasion, meaning cancer cells had invaded blood vessels at multiple sites, a well-established risk factor for distant metastasis. Importantly, the surgical margins were negative, and there was no extrathyroidal extension, meaning the tumor had not grown through the thyroid capsule into surrounding neck structures. Lymph node analysis revealed metastatic disease in seven of thirteen central nodes and three of six right lateral nodes, resulting in a pathological stage of pT3a pN1b.

What happened next illustrates both the promise and the limitations of radioactive iodine therapy, the hallmark systemic treatment for differentiated thyroid cancer. Radioactive iodine exploits a unique property of thyroid cells: their ability to actively transport iodine through the sodium-iodide symporter. When differentiated thyroid cancer cells retain this transporter, they can be selectively irradiated from within by ingested radioactive iodine, a treatment with comparatively few side effects because non-thyroid tissues absorb little of the isotope. A diagnostic scan performed in September 2024 demonstrated that the patient’s mediastinal and pulmonary metastases were iodine-avid, meaning the lung and chest deposits visibly concentrated the radioactive tracer. This finding classified her disease as distant metastatic disease, designated cM1, but also offered genuine hope, because iodine-avid metastases are typically considered candidates for effective radioiodine ablation.

Two courses of radioactive iodine treatment were documented. Initial follow-up appeared encouraging: imaging in March 2025 showed improvement in the pulmonary metastases, and the treatment team had reason to believe the iodine-avid disease was responding. However, the trajectory shifted over the following months. By June 2025, the patient’s serum thyroglobulin, a protein produced almost exclusively by thyroid tissue and widely used as a tumor marker for differentiated thyroid cancer after thyroidectomy, had climbed to 656.85 nanograms per milliliter, a level far above the near-undetectable values expected in disease-free patients. In September 2025, pulmonary computed tomography revealed mixed changes, with some lesions improving while others progressed or evolved, and thyroglobulin remained above 500 nanograms per milliliter, confirming that substantial metabolically active thyroid cancer tissue persisted despite therapy.

The reporting authors are appropriately careful about what these findings do and do not prove. Because the exact administered radioactive iodine activities were missing from the record and the imaging and biochemical tests were not fully synchronized in time, the case cannot be definitively classified as radioactive iodine-refractory disease, the formal designation for tumors that either never take up iodine or progress after appropriate radioiodine treatment. This distinction matters enormously for clinical decision-making, since refractory disease opens the door to kinase inhibitors and other targeted therapies, while iodine-avid disease generally argues for repeated radioiodine courses. The authors also note a subtle but important point of precision: the frequently cited 13-centimeter figure describes the clinical mass measured in the neck, not the diameter of a single pathological tumor specimen, a reminder that careful measurement conventions matter when comparing cases across the literature.

Longitudinal evidence on giant thyroid tumors treated with radioactive iodine remains limited, which is precisely why this case report includes a focused review of the existing literature. Most large series of differentiated high-grade thyroid carcinoma emphasize its intermediate position on the aggressiveness spectrum: distinctly worse than conventional papillary and follicular carcinoma, yet generally less explosive than poorly differentiated carcinoma or anaplastic thyroid carcinoma, the almost uniformly fatal undifferentiated form. Differentiated high-grade tumors carry elevated rates of recurrence and distant metastasis, and the presence of necrosis and high mitotic activity has been linked to poorer disease-specific survival in multiple studies. This case adds a valuable data point by documenting the full arc from giant untreated primary tumor through surgery, radioiodine response, and eventual biochemical and radiographic progression over roughly two years of follow-up.

At last contact on August 26, 2026, the patient was alive and reported generalized pain and low-back pain, symptoms that raise the specter of skeletal metastasis, a common distant site for aggressive thyroid cancer, although no imaging confirmation of new metastases was available at the time of the report. Her course delivers several sobering lessons for clinicians and patients alike. First, differentiated appearance on the microscope does not guarantee indolent behavior once necrosis and brisk mitotic activity are present, so the 2022 WHO criteria deserve active application in every thyroid pathology report. Second, early post-treatment improvement after radioactive iodine does not establish durable control, and biochemical surveillance with thyroglobulin remains indispensable for catching treatment failure. Third, slowly enlarging neck masses deserve evaluation long before they become symptomatic, because a six-year delay transformed a potentially straightforward thyroidectomy into a major oncological operation with distant disease already established. As differentiated high-grade thyroid carcinoma becomes more widely recognized, cases like this one will help define its natural history and sharpen the decisions that follow.

Subject of Research: Differentiated high-grade thyroid carcinoma presenting as a giant neck mass with iodine-avid pulmonary metastases

Article Title: Diffuse bilateral differentiated high-grade thyroid carcinoma presenting as a giant clinical neck mass with iodine-avid pulmonary metastases: a case report and focused literature review

Article References: Gao, S., Xu, X., & Wei, W. (2026). Diffuse bilateral differentiated high-grade thyroid carcinoma presenting as a giant clinical neck mass with iodine-avid pulmonary metastases: a case report and focused literature review. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02559-6

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02559-6

Keywords: differentiated high-grade thyroid carcinoma, thyroid cancer, giant neck mass, pulmonary metastasis, radioactive iodine, total thyroidectomy, thyroglobulin, WHO classification 2022, case report, lymph node metastasis, endocrine cancer, BMC Endocrine Disorders